
Who's online
There are currently 1 user and 210 guests online.
Online users
- Bart Knols
News Flash
Latest Jobs
Events 2010
Recent blog posts
- We thought we were down to 655.000 deaths in 2010, right?
- Job: Postdoctoral Fellow: Malaria resistance research
- Let the sun shine
- Postdoctoral Fellows: Malaria research
- Guest Editorial: Don't fake it!
- Loop mediated amplification question
- Criticism, Ideas and the Maya example
- Symposium: Malaria 2012: Drugs, Vaccines, and Pathogenesis
- OPEN ACCESS TO PUBLICLY FUNDED RESEARCH: PUBLISHERS ARE ACTING UP
- The last 'Last week at MalariaWorld' of 2011...a special message for you.
In this regard, the advent of rapid diagnostic tests (RDTs) for malaria is an important advance. Multiple immunochromatographic tests, incorporating a number of different parasite antigens and produced by many different manufacturers, are now available.
The risk factors associated with gametocytaemia at presentation and after ACTs were evaluated in 835 children assigned to artesunate, artesunate-amodiaquine, artesunate-mefloquine or artemether-lumefantrine.
Malaria, caused by Plasmodium sp, results in almost one million deaths and over 200 million new infections annually.
This snapshot questionnaire survey aimed to provide an overview on the current routine practices for the availability and use P-ACT as anti-malarial treatment for young children in sub-Saharan Africa.
This study resulted in notifications to all state drug controllers in India to withdraw the oral artemisinin formulations from the market. In 2010, artesunate + sulphadoxine-pyrimethamine became the universal first-line treatment for confirmed Plasmodium falciparum malaria and was deployed at full scale.
The emergence of multidrug-resistant strains of Plasmodium spp., the etiological agent of malaria, constitutes a major threat to controlling the disease1, 2.
We did a longitudinal study of inhabitants of Dielmo village, Senegal, between January, 2007, and December, 2010. We monitored the inhabitants for fever during this period and we treated malaria attacks with artesunate plus amodiaquine.
In this article, we conducted a systematic review and meta-analysis to evaluate the antischistosomal efficacy of different medication strategies including monotherapy or combination therapies of these drugs.
The novel mode of action of dehydrobrachylaenolide, detected during these studies, will play an ongoing role in advancing anti- plasmodial drug discovery efforts.